The LSC has decided to cease funding a group action by epileptic mothers who claim that taking the drug Epilim while pregnant caused birth defects in their children.
Richard Waite and Susan Riitala round up the coalition's overhaul of the regulators and consider the implications of that European privilege ruling on competition lawyers